High miR-202-5p Expression at Initial Diagnosis is Associated With Tyrosine Kinase Inhibitor Resistance In Chronic Myeloid Leukemia-A Result From a Nested Case-Control Study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
31 patients who developed TKI resistance (per ELN 2020 criteria, without ABL mutations) were matched 1:4 to 124 TKI-sensitive controls on age, sex, Sokal score, and baseline white blood cell count.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings support its potential as a clinical biomarker for identifying high-risk patients, which could aid in early risk stratification and guide therapeutic strategy. [TRIAL REGISTRATION] The authors have confirmed clinical trial registration is not needed for this submission.
[BACKGROUND] Tyrosine kinase inhibitor (TKI) resistance remains a critical challenge in chronic myeloid leukemia (CML).
- 95% CI 4.87-47.51
- OR 15.21
- 연구 설계 case-control
APA
Nie ZY, Wang J, et al. (2026). High miR-202-5p Expression at Initial Diagnosis is Associated With Tyrosine Kinase Inhibitor Resistance In Chronic Myeloid Leukemia-A Result From a Nested Case-Control Study.. EJHaem, 7(1), e70240. https://doi.org/10.1002/jha2.70240
MLA
Nie ZY, et al.. "High miR-202-5p Expression at Initial Diagnosis is Associated With Tyrosine Kinase Inhibitor Resistance In Chronic Myeloid Leukemia-A Result From a Nested Case-Control Study.." EJHaem, vol. 7, no. 1, 2026, pp. e70240.
PMID
41694089 ↗
Abstract 한글 요약
[BACKGROUND] Tyrosine kinase inhibitor (TKI) resistance remains a critical challenge in chronic myeloid leukemia (CML). While mechanistic studies implicate miR-202-5p in resistance, its clinical relevance as a biomarker at diagnosis requires validation.
[METHODS] A nested case-control design was employed within a prospective cohort of 797 newly diagnosed chronic-phase CML patients. Of these, 31 patients who developed TKI resistance (per ELN 2020 criteria, without ABL mutations) were matched 1:4 to 124 TKI-sensitive controls on age, sex, Sokal score, and baseline white blood cell count. miR-202-5p expression was quantified by qRT-PCR from diagnostic peripheral blood mononuclear cells (PBMCs). Statistical analyses included conditional logistic regression and receiver operating characteristic (ROC) curve analysis.
[RESULTS] The expression level of miR-202-5p was significantly elevated in the TKI-resistant group (1.68 ± 0.45) compared to the TKI-sensitive group (1.26 ± 0.32) ( < 0.001). Conditional logistic regression analysis revealed that elevated miR-202-5p expression was strongly correlated with an increased risk of TKI resistance (OR = 15.21, 95% CI: 4.87-47.51; < 0.001). ROC curve analysis demonstrated that miR-202-5p had moderate diagnostic accuracy for identifying TKI resistance (AUC = 0.73, 95% CI: 0.65-0.81). Using the optimal cut-off value of 1.63 determined by the Youden Index, the proportion of TKI resistance was significantly higher in the high-expression group (61.29% vs. 12.10%, < 0.001).
[CONCLUSION] Elevated miR-202-5p expression at diagnosis is significantly associated with TKI resistance in CML. These findings support its potential as a clinical biomarker for identifying high-risk patients, which could aid in early risk stratification and guide therapeutic strategy.
[TRIAL REGISTRATION] The authors have confirmed clinical trial registration is not needed for this submission.
[METHODS] A nested case-control design was employed within a prospective cohort of 797 newly diagnosed chronic-phase CML patients. Of these, 31 patients who developed TKI resistance (per ELN 2020 criteria, without ABL mutations) were matched 1:4 to 124 TKI-sensitive controls on age, sex, Sokal score, and baseline white blood cell count. miR-202-5p expression was quantified by qRT-PCR from diagnostic peripheral blood mononuclear cells (PBMCs). Statistical analyses included conditional logistic regression and receiver operating characteristic (ROC) curve analysis.
[RESULTS] The expression level of miR-202-5p was significantly elevated in the TKI-resistant group (1.68 ± 0.45) compared to the TKI-sensitive group (1.26 ± 0.32) ( < 0.001). Conditional logistic regression analysis revealed that elevated miR-202-5p expression was strongly correlated with an increased risk of TKI resistance (OR = 15.21, 95% CI: 4.87-47.51; < 0.001). ROC curve analysis demonstrated that miR-202-5p had moderate diagnostic accuracy for identifying TKI resistance (AUC = 0.73, 95% CI: 0.65-0.81). Using the optimal cut-off value of 1.63 determined by the Youden Index, the proportion of TKI resistance was significantly higher in the high-expression group (61.29% vs. 12.10%, < 0.001).
[CONCLUSION] Elevated miR-202-5p expression at diagnosis is significantly associated with TKI resistance in CML. These findings support its potential as a clinical biomarker for identifying high-risk patients, which could aid in early risk stratification and guide therapeutic strategy.
[TRIAL REGISTRATION] The authors have confirmed clinical trial registration is not needed for this submission.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.
- Safe discharge on the second postoperative day after major colorectal surgery: a decision-making strategy based on quantitative serological data.